Literature DB >> 8459058

Do false positive thallium-201 scans lead to unnecessary catheterization? Outcome of patients with perfusion defects on quantitative planar thallium-201 scintigraphy.

R L Desmarais1, S Kaul, D D Watson, G A Beller.   

Abstract

OBJECTIVES: We postulated that artifactually abnormal thallium-201 scans are well identified at the time of initial clinical interpretation by experienced readers and do not lead to unnecessary coronary angiography.
BACKGROUND: Exercise thallium-201 scintigraphy employing quantitative imaging techniques has yielded sensitivity and specificity values of 80% to 90%. There are image artifacts, such as breast shadows, and variants of normal that, if not correctly identified, can lead to a high false positive rate for detection of coronary artery disease.
METHODS: Data from 338 consecutive patients with one or more focal thallium-201 defects on quantitative planar images were reviewed. All patients had undergone symptom-limited exercise scintigraphy and were classified as having either artifactual or nonartifactual thallium-201 defects after review of clinical reports.
RESULTS: Of the 265 patients with defects judged to be nonartifactual on clinical readings, 167 underwent coronary angiography, which demonstrated significant coronary artery disease (> or = 50% stenosis) in 161 (96%) and normal findings in 6. Four of the latter six had documented prior myocardial infarction. The remaining 73 patients (85% female) had thallium-201 defects deemed to be artifactual on clinical readings, chiefly as a result of breast (66%) and diaphragmatic (8%) attenuation or variants of normal (26%). Only 4 (5%) of the 73 patients underwent subsequent coronary angiography; none had coronary artery disease. One had aortic stenosis and two had variant angina. Follow-up (mean 20 +/- 2 months) of the 69 patients in this group who did not undergo coronary angiography revealed no deaths and one nonfatal non-Q wave myocardial infarction.
CONCLUSIONS: Artifactual defects on quantitative planar thallium-201 scintigraphy are well recognized by experienced interpreters and do not result in a high false positive rate leading to unnecessary cardiac catheterization. The incidence of coronary artery disease is high in patients with thallium-201 defects judged to be nonartifactual, and many patients with perfusion defects and angiographically normal coronary arteries have organic heart disease.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8459058     DOI: 10.1016/0735-1097(93)90225-p

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  5 in total

1.  Clinical validation of SPECT attenuation correction using x-ray computed tomography-derived attenuation maps: multicenter clinical trial with angiographic correlation.

Authors:  Yasmin Masood; Yi-Hwa Liu; Gordon Depuey; Raymond Taillefer; Luis I Araujo; Steven Allen; Dominique Delbeke; Frank Anstett; Aharon Peretz; Mary-Jo Zito; Vera Tsatkin; Frans J Th Wackers
Journal:  J Nucl Cardiol       Date:  2005 Nov-Dec       Impact factor: 5.952

2.  Myocardial perfusion defects in left bundle branch block: true or false? Fact or artifact?

Authors:  F J Wackers
Journal:  J Nucl Cardiol       Date:  1997 Nov-Dec       Impact factor: 5.952

3.  Do imaging studies performed in physician offices increase downstream utilization?: an empiric analysis of cardiac stress testing with imaging.

Authors:  Jersey Chen; Reza Fazel; Joseph S Ross; Robert L McNamara; Andrew J Einstein; Mouaz Al-Mallah; Harlan M Krumholz; Brahmajee K Nallamothu
Journal:  JACC Cardiovasc Imaging       Date:  2011-06

Review 4.  Sex specific issues relating to nuclear cardiology.

Authors:  L L Johnson
Journal:  J Nucl Cardiol       Date:  1995 Jul-Aug       Impact factor: 5.952

5.  Coronary angiographic rates after stress single-photon emission computed tomographic scintigraphy.

Authors:  T M Bateman; J H O'Keefe; V M Dong; C Barnhart; R W Ligon
Journal:  J Nucl Cardiol       Date:  1995 May-Jun       Impact factor: 5.952

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.